- Caribou Biosciences ( NASDAQ: CRBU ) is down 10% Monday morning after reporting 12-month phase 1 data for CB-010, its allogeneic anti-CD19 CAR-T cell therapy candidate .
- Data from a cohort of six patients with B cell non-Hodgkin lymphoma showed that half maintained a durable complete response ( CR ) at six months, with two patients demonstrating a CR at 12 months.
- Patients were given a single infusion.
- Caribou ( CRBU ) noted that CB-010 was generally well tolerated with adverse events consistent with autologous or allogeneic anti-CD19 CAR-T cell therapies
- The company plans a further data update in 2023.
- Seeking Alpha's Quant Rating views Caribou ( CRBU ) as a hold with strong marks for profitability and momentum .
For further details see:
Caribou Biosciences off 10% following early-stage allogenic CAR-T cell therapy data